(Career Enhancement Program) The goal of the Career Enhancement Program (CEP) is to provide training and guidance for academic physician-scientists, clinician-investigators, and laboratory-based scientists who wish to dedicate their career and research efforts to leukemia translational research. To achieve this goal, the CEP will pursue the following specific aims: 1. Recruit, train, and mentor physicians, scientists, and senior postdoctoral fellows to become excellent leukemia investigators focused on leukemia translational research. 2. Educate awardees in all the basic principles of cancer and leukemia biology, including molecular, cellular and systems biology, drug development, pharmacokinetic and pharmacodynamics studies, and basic principles of biostatistics and bioinformatics. 3. Provide a firm foundation for awardees in the specific area of leukemia translational and early clinical research. These objectives will be achieved through strong mentorship in which awardees will be instructed in the principles of clinical, basic, and translational leukemia research. Specific areas of education will include scientific and clinical methods, biomedical ethics, statistical design and analysis, bioinformatics, biology, biochemistry, genetics, epidemiology, and other areas relevant to individual projects. Mentorship will include laboratory-based investigators, clinical-translational investigators, biostatisticians, bioinformaticians and epidemiologists. Mentors from within the Leukemia SPORE and the other 1,500 faculty members at the MD Anderson Cancer Center, Graduate School of Biomedical Sciences, Fox Chase Cancer Center and from the University of Texas in Houston, will provide the expertise required for the development of strong, productive translational research skills. Since its inception in 2003, the CEP has funded 54 awards given to 36 recipients, including 14 women and 14 minorities, who have gained skills and expertise in designing and conducting clinical translational-based studies in leukemia, including incorporating laboratory-based studies in clinical trials and, conversely, transforming critical clinical observations into meaningful laboratory investigations. The majority have continued independent academic careers in leukemia or cancer research. Thus, this program has contributed to the career development of talented young leukemia investigators to hasten the development of effective new therapeutic strategies against leukemia.

Public Health Relevance

(Career Enhancement Program) The Career Enhancement Program fosters the scientific development of investigators who intend to focus their careers on translational studies of leukemia. This is achieved by recruiting innovative entry-level scientists to enhance the SPORE?s overall translational research capability, helping these individuals develop intellectual and technical skills required to be productive investigators, and teaching these individuals basic principles of translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-18
Application #
10006819
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2003-08-05
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Kayser, Sabine; Levis, Mark J (2018) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol 180:484-500
Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Boddu, P; Jorgensen, J; Kantarjian, H et al. (2018) Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32:241-244
Yan, Fangrong; Zhu, Huihong; Liu, Junlin et al. (2018) Design and inference for 3-stage bioequivalence testing with serial sampling data. Pharm Stat 17:458-476
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831

Showing the most recent 10 out of 487 publications